We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
G020: Valsartan provides effective antihypertensive response in older patients: An integrated analysis.
- Authors
Oparil, S.; Pool, J.; Hedner, T.; Glazer, R.; Chiang, Y.
- Abstract
The response to some antihypertensive therapies may be affected by age. Valsartan is a potent, highly selective angiotensin II receptor blocker used to treat hypertension. This study examines the efficacy of valsartan among older and younger patients.An integrated analysis was performed on 9 randomized placebo-controlled valsartan trials of similar design. 4067 patients with hypertension were included in the efficacy analysis and received valsartan 10-320 mg or placebo once daily (od) for a minimum of 4 wk. 30% were ≥65 years old (older). Statistical analysis was done using ANCOVA.Clinically relevant blood pressure (BP) reductions were achieved at doses ≥80 mg. 998 older patients received valsartan 80 mg (n=459), 160 mg (n=172), 320 mg (n=25), or placebo (n=342). 2518 younger patients received valsartan 80 mg (n=1334), 160 mg (n=235), 320 mg (n=125), or placebo (n=824). (See Table)Valsartan 80-320 mg od produced statistically significant reductions in systolic (P<0.0001) and diastolic (P<0.05) BP compared with placebo in both older and younger patients. Systolic BP reductions tended to be greater in older compared with younger hypertensives. The antihypertensive response increased with increasing dose.Conclusion: Valsartan is effective in the treatment of hypertension irrespective of age. The antihypertensive response is dose dependent for both older and younger patients.Am J Hypertens (2000) 13, 259A-260A; doi:S0895-7061(00)00981-X
- Publication
American Journal of Hypertension, 2000, Vol 13, p259A
- ISSN
0895-7061
- Publication type
Article
- DOI
10.1016/S0895-7061(00)00981-X